Revadix
Revadix is developing small molecule therapies that specifically target EPAC1, a novel, validated pathway responsible for deleterious signalling in several pathological conditions as in atrial fibrialltion. This innovative approach is based on the research conducted by Frank Lezoualc’h, Research Director at Inserm within the Institute of Metabolic and Cardiovascular Diseases, Toulouse, France.
Company Focus
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, with significant long-term health implications. Currently, 89 million individuals worldwide are affected by AF, increasing their risk of heart failure, stroke, neurodegenerative disorder and myocardial infarction. Furthermore, postoperative atrial fibrillation occurs in 30-50% of patients undergoing cardiac surgeries. Treatment options for AF remain limited, leaving many patients unable to effectively manage the condition.
Our Technology
We are advancing the development of AM-001, a patented EPAC-1 inhibitor that demonstrates exceptional specificity and efficacy in vitro, in vivo preclinical models, and AF patient myocytes. Revadix focuses on creating innovative small molecule therapies that precisely target this validated, novel pathway known to be at the genesis of various pathological cardiac conditions, thereby safeguarding essential cardiac function.
Company Status
Revadix employs a dual-program strategy to drive innovation and impact in delivering safe, non-invasive and cost-effective treatments for cardiac rhythm disturbances. Program 1 is advancing through lead optimization towards development candidate nomination, with plans to scale up its lead asset and begin IND-enabling toxicology studies. Together, we can pioneer transformative treatments, empowering millions of patients to reclaim control of their lives.
News from Revadix
PRESS RELEASE
NLC Health Ventures introduces new venture transforming cardiovascular care NLC Health Ventures launches Revadix, an innovative biotech venture focused on improving the lives of millions
April 11, 2025